Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections
Autore:
Ferwerda, A; Moll, HA; Hop, WCJ; Kouwenberg, JM; Gi, CVTP; Robben, SGF; de Groot, R;
Indirizzi:
Univ Rotterdam Hosp, Sophia Childrens Hosp, Dept Paediat, Rotterdam, Netherlands Univ Rotterdam Hosp Rotterdam Netherlands ediat, Rotterdam, Netherlands Erasmus Univ, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands Erasmus Univ Rotterdam Netherlands NL-3000 DR DR Rotterdam, Netherlands Juliana Childrens Hosp, The Hague, Netherlands Juliana Childrens Hosp TheHague Netherlands sp, The Hague, Netherlands Groene Hart Hosp, Dept Pediat, Gouda, Netherlands Groene Hart Hosp GoudaNetherlands osp, Dept Pediat, Gouda, Netherlands Univ Rotterdam Hosp, Sophia Childrens Hosp, Dept Paediat Radiol, Rotterdam, Netherlands Univ Rotterdam Hosp Rotterdam Netherlands adiol, Rotterdam, Netherlands
Titolo Testata:
Journal of antimicrobial chemotherapy
fascicolo: 4, volume: 47, anno: 2001,
pagine: 441 - 446
Fonte:
ISI
Lingua:
ENG
Soggetto:
ERYTHROMYCIN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
13
Recensione:
Indirizzi per estratti:
Indirizzo: de Groot, R Sophia Childrens Hosp, POB 2060, NL-3000 CB Rotterdam, Netherlands Sophia Childrens Hosp POB 2060 Rotterdam Netherlands NL-3000 CB
Citazione:
A. Ferwerda et al., "Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections", J ANTIMICRO, 47(4), 2001, pp. 441-446

Abstract

To compare the efficacy, safety and tolerability of a 3 day course of azithromycin with a 10 day course of co-amoxiclav in the treatment of children with acute lower respiratory tract infection (LRTI), 118 patients with community-acquired LRTI were included in a multicentre randomized double-blind,double-dummy study. The diagnosis of LRTI was based on the presence of respiratory signs and symptoms in combination with consolidation on a chest radiograph or clinical evidence of LRTI. Patients received oral azithromycin suspension (10 mg/kg/24 h) or placebo in one dose for 3 days and co-amoxiclav (45/11.25 mg/kg/24 h) or placebo in three doses for 10 days. Of 110 eligible patients, 56 and 54 patients, respectively, were treated with azithromycin or co-amoxiclav. The percentage of patients cured or clinically improved at days 10-13 (primary endpoint) was 91% for azithromycin and 87% for co-amoxiclav. This difference of 4% (90% confidence interval: -6%, +14%) was not statistically significant (P = 0.55). Significantly (P = 0.01) move related adverse events were found in the co-amoxiclav group. This was largely due to a higher percentage (43% versus 19%) of gastrointestinal complaints. A 3 day course of azithromycin (three doses) is as effective in the treatment of LRTI in children as a 10 day course of co-amoxiclav (30 doses). The azithromycin group had fewer adverse events. We conclude that azithromycin is an effective, safe and well-tolerated drug in the treatment of children with LRTI. An additional advantage is the easy administration and short duration of therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/09/20 alle ore 16:57:51